세계의 비근침윤성 방광암 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for non-muscle invasive bladder cancer (NMIBC) therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and insights that highlight the evolving landscape of bladder cancer treatment options.

Key Insights:

• Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2025E): 3,160.6 Million
• Projected Market Value (2032F): USD 8,006.3 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 14.2%

Non-muscle Invasive Bladder Cancer Therapeutics Market - Report Scope:

The NMIBC therapeutics market encompasses a range of pharmaceutical and immunotherapeutic options designed to treat bladder tumors that have not yet invaded the muscle layer of the bladder wall. Key treatments include Bacillus Calmette-Guerin (BCG) therapy, chemotherapy instillations, immuno-oncology agents, and novel targeted therapies. The market serves hospitals, urology clinics, ambulatory surgical centers, and cancer research institutions. Increasing incidence of bladder cancer, favorable clinical outcomes from intravesical therapies, and advancements in biomarker-based precision medicine are fueling the market's expansion.

Market Growth Drivers:

The global NMIBC therapeutics market is propelled by several key factors, including the rising global prevalence of bladder cancer and increased awareness regarding early diagnosis and treatment. Widespread adoption of BCG therapy and growing clinical acceptance of checkpoint inhibitors and gene therapy-based solutions have significantly boosted treatment options. Additionally, innovations in intravesical drug delivery methods, improved patient risk stratification through molecular diagnostics, and government-led initiatives to promote cancer screening are contributing to market growth. The increasing elderly population, which is more prone to bladder cancer, further drives demand for effective and minimally invasive therapies.

Market Restraints:

Despite favorable growth prospects, the NMIBC therapeutics market faces challenges such as drug shortages, particularly BCG supply constraints, and adverse effects associated with existing therapies, which limit patient compliance. Regulatory hurdles for the approval of novel biologics and high development costs also pose barriers for new entrants. Moreover, the recurrence and progression rates associated with NMIBC require long-term treatment and surveillance, placing financial pressure on healthcare systems and patients, especially in low- and middle-income countries.

Market Opportunities:

Significant opportunities lie in the development of non-invasive diagnostic biomarkers and next-generation immunotherapies that enhance therapeutic precision. Growing interest in personalized medicine and the integration of artificial intelligence for predicting recurrence and treatment response are creating new frontiers. Additionally, expanding research into combination therapies and the use of novel delivery mechanisms, such as thermochemotherapy and drug-eluting devices, holds strong promise. Collaborations between academic institutions and biopharmaceutical companies, alongside increased funding for urologic oncology research, can unlock new therapeutic avenues and accelerate innovation in the NMIBC space.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the NMIBC therapeutics market globally?
• Which therapeutic modalities are most widely adopted for NMIBC treatment across different healthcare settings?
• How are technological advancements in drug delivery and diagnostics shaping the NMIBC treatment landscape?
• Who are the key players contributing to the NMIBC therapeutics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global NMIBC therapeutics market?

Competitive Intelligence and Business Strategy:

These companies are actively investing in clinical trials for novel immune checkpoint inhibitors, recombinant BCG strains, and gene therapies targeting high-risk patient populations. Partnerships with diagnostic companies to develop companion diagnostics and collaborations with cancer centers for real-world studies enhance their market presence. Emphasis on patient-centric treatment models and expansion into emerging markets are also critical components of their business strategy.

Key Companies Profiled:

• Pfizer Inc.
• Merck KGaA
• AstraZeneca PLC
• Roche Holding AG (Genentech)
• Astellas Pharma Inc.
• J&J (Janssen Biotech)
• Cipla Inc.
• Amneal Pharma
• Bristol Myers Squibb Co.
• Dr. Reddy's Laboratories, Inc.
• Gilead Sciences Inc.
• Endo Pharma
• UroGen Pharma, Inc.
• Teva Pharmaceuticals (Actavis)

Non-muscle Invasive Bladder Cancer Therapeutics Market Research Segmentation:

Cancer Grade:

• Low-grade Bladder Cancer
• High-grade Bladder Cancer

Drug Type:

• Immunotherapy

* Bacillus Calmette-Guerin

* Avelumab

* Nivolumab

* Pembrolizumab

* Others

• Chemotherapy

* Mitomycin C

* Docetaxel

* Paclitaxel

* Cisplatin

* Others

• Targeted Therapy

* Erdafitinib

* Enfortumab Vedotin-ejfv

* Sacituzumab Govitecan

* Others

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Snapshot 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Industry Developments and Key Market Events
• 1.5. Demand Side and Supply Side Analysis
• 1.6. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definitions
• 2.2. Value Chain Analysis
• 2.3. Macro-Economic Factors
  • 2.3.1. Global GDP Outlook
  • 2.3.2. Global Construction Industry Overview
  • 2.3.3. Global Mining Industry Overview
• 2.4. Forecast Factors - Relevance and Impact
• 2.5. COVID-19 Impact Assessment
• 2.6. PESTLE Analysis
• 2.7. Porter's Five Forces Analysis
• 2.8. Geopolitical Tensions: Market Impact
• 2.9. Regulatory and Technology Landscape

3. Market Dynamics

• 3.1. Drivers
• 3.2. Restraints
• 3.3. Opportunities
• 3.4. Trends

4. Price Trend Analysis, 2019-2032

• 4.1. Region-wise Price Analysis
• 4.2. Price by Segments
• 4.3. Price Impact Factors

5. Global Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 5.1. Key Highlights
• 5.2. Global Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Cancer Grade
  • 5.2.1. Introduction/Key Findings
  • 5.2.2. Historical Market Size (US$ Mn) Analysis by Cancer Grade, 2019-2024
  • 5.2.3. Current Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
    • 5.2.3.1. Low-grade Bladder Cancer
    • 5.2.3.2. High-grade Bladder Cancer
  • 5.2.4. Market Attractiveness Analysis: Cancer Grade
• 5.3. Global Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Drug Type
  • 5.3.1. Introduction/Key Findings
  • 5.3.2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2019-2024
  • 5.3.3. Current Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
    • 5.3.3.1. Immunotherapy
      • 5.3.3.1.1. Bacillus Calmette-Guerin
      • 5.3.3.1.2. Avelumab
      • 5.3.3.1.3. Nivolumab
      • 5.3.3.1.4. Pembrolizumab
      • 5.3.3.1.5. Others
    • 5.3.3.2. Chemotherapy
      • 5.3.3.2.1. Mitomycin C
      • 5.3.3.2.2. Docetaxel
      • 5.3.3.2.3. Paclitaxel
      • 5.3.3.2.4. Cisplatin
      • 5.3.3.2.5. Others
    • 5.3.3.3. Targeted Therapy
      • 5.3.3.3.1. Erdafitinib
      • 5.3.3.3.2. Enfortumab Vedotin-ejfv
      • 5.3.3.3.3. Sacituzumab Govitecan
      • 5.3.3.3.4. Others
  • 5.3.4. Market Attractiveness Analysis: Drug Type
• 5.4. Global Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Distribution Channel
  • 5.4.1. Introduction/Key Findings
  • 5.4.2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2019-2024
  • 5.4.3. Current Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
    • 5.4.3.1. Hospital Pharmacies
    • 5.4.3.2. Retail Pharmacies
    • 5.4.3.3. Specialty Pharmacies
    • 5.4.3.4. Online Pharmacies
  • 5.4.4. Market Attractiveness Analysis: Distribution Channel

6. Global Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Region

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis by Region, 2019-2024
• 6.3. Current Market Size (US$ Mn) Forecast, by Region, 2025-2032
  • 6.3.1. North America
  • 6.3.2. Europe
  • 6.3.3. East Asia
  • 6.3.4. South Asia & Oceania
  • 6.3.5. Latin America
  • 6.3.6. Middle East & Africa
• 6.4. Market Attractiveness Analysis: Region

7. North America Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. North America Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 7.3.1. U.S.
  • 7.3.2. Canada
• 7.4. North America Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 7.4.1. Low-grade Bladder Cancer
  • 7.4.2. High-grade Bladder Cancer
• 7.5. North America Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 7.5.1. Immunotherapy
    • 7.5.1.1. Bacillus Calmette-Guerin
    • 7.5.1.2. Avelumab
    • 7.5.1.3. Nivolumab
    • 7.5.1.4. Pembrolizumab
    • 7.5.1.5. Others
  • 7.5.2. Chemotherapy
    • 7.5.2.1. Mitomycin C
    • 7.5.2.2. Docetaxel
    • 7.5.2.3. Paclitaxel
    • 7.5.2.4. Cisplatin
    • 7.5.2.5. Others
  • 7.5.3. Targeted Therapy
    • 7.5.3.1. Erdafitinib
    • 7.5.3.2. Enfortumab Vedotin-ejfv
    • 7.5.3.3. Sacituzumab Govitecan
    • 7.5.3.4. Others
• 7.6. North America Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Retail Pharmacies
  • 7.6.3. Specialty Pharmacies
  • 7.6.4. Online Pharmacies

8. Europe Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Europe Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 8.3.1. Germany
  • 8.3.2. Italy
  • 8.3.3. France
  • 8.3.4. U.K.
  • 8.3.5. Spain
  • 8.3.6. Russia
  • 8.3.7. Rest of Europe
• 8.4. Europe Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 8.4.1. Low-grade Bladder Cancer
  • 8.4.2. High-grade Bladder Cancer
• 8.5. Europe Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 8.5.1. Immunotherapy
    • 8.5.1.1. Bacillus Calmette-Guerin
    • 8.5.1.2. Avelumab
    • 8.5.1.3. Nivolumab
    • 8.5.1.4. Pembrolizumab
    • 8.5.1.5. Others
  • 8.5.2. Chemotherapy
    • 8.5.2.1. Mitomycin C
    • 8.5.2.2. Docetaxel
    • 8.5.2.3. Paclitaxel
    • 8.5.2.4. Cisplatin
    • 8.5.2.5. Others
  • 8.5.3. Targeted Therapy
    • 8.5.3.1. Erdafitinib
    • 8.5.3.2. Enfortumab Vedotin-ejfv
    • 8.5.3.3. Sacituzumab Govitecan
    • 8.5.3.4. Others
• 8.6. Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Retail Pharmacies
  • 8.6.3. Specialty Pharmacies
  • 8.6.4. Online Pharmacies

9. East Asia Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. East Asia Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. South Korea
• 9.4. East Asia Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 9.4.1. Low-grade Bladder Cancer
  • 9.4.2. High-grade Bladder Cancer
• 9.5. East Asia Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 9.5.1. Immunotherapy
    • 9.5.1.1. Bacillus Calmette-Guerin
    • 9.5.1.2. Avelumab
    • 9.5.1.3. Nivolumab
    • 9.5.1.4. Pembrolizumab
    • 9.5.1.5. Others
  • 9.5.2. Chemotherapy
    • 9.5.2.1. Mitomycin C
    • 9.5.2.2. Docetaxel
    • 9.5.2.3. Paclitaxel
    • 9.5.2.4. Cisplatin
    • 9.5.2.5. Others
  • 9.5.3. Targeted Therapy
    • 9.5.3.1. Erdafitinib
    • 9.5.3.2. Enfortumab Vedotin-ejfv
    • 9.5.3.3. Sacituzumab Govitecan
    • 9.5.3.4. Others
• 9.6. East Asia Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Retail Pharmacies
  • 9.6.3. Specialty Pharmacies
  • 9.6.4. Online Pharmacies

10. South Asia & Oceania Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. South Asia & Oceania Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 10.3.1. India
  • 10.3.2. Southeast Asia
  • 10.3.3. ANZ
  • 10.3.4. Rest of SAO
• 10.4. South Asia & Oceania Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 10.4.1. Low-grade Bladder Cancer
  • 10.4.2. High-grade Bladder Cancer
• 10.5. South Asia & Oceania Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 10.5.1. Immunotherapy
    • 10.5.1.1. Bacillus Calmette-Guerin
    • 10.5.1.2. Avelumab
    • 10.5.1.3. Nivolumab
    • 10.5.1.4. Pembrolizumab
    • 10.5.1.5. Others
  • 10.5.2. Chemotherapy
    • 10.5.2.1. Mitomycin C
    • 10.5.2.2. Docetaxel
    • 10.5.2.3. Paclitaxel
    • 10.5.2.4. Cisplatin
    • 10.5.2.5. Others
  • 10.5.3. Targeted Therapy
    • 10.5.3.1. Erdafitinib
    • 10.5.3.2. Enfortumab Vedotin-ejfv
    • 10.5.3.3. Sacituzumab Govitecan
    • 10.5.3.4. Others
• 10.6. South Asia & Oceania Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Retail Pharmacies
  • 10.6.3. Specialty Pharmacies
  • 10.6.4. Online Pharmacies

11. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Latin America Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 11.3.1. Brazil
  • 11.3.2. Mexico
  • 11.3.3. Rest of LATAM
• 11.4. Latin America Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 11.4.1. Low-grade Bladder Cancer
  • 11.4.2. High-grade Bladder Cancer
• 11.5. Latin America Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 11.5.1. Immunotherapy
    • 11.5.1.1. Bacillus Calmette-Guerin
    • 11.5.1.2. Avelumab
    • 11.5.1.3. Nivolumab
    • 11.5.1.4. Pembrolizumab
    • 11.5.1.5. Others
  • 11.5.2. Chemotherapy
    • 11.5.2.1. Mitomycin C
    • 11.5.2.2. Docetaxel
    • 11.5.2.3. Paclitaxel
    • 11.5.2.4. Cisplatin
    • 11.5.2.5. Others
  • 11.5.3. Targeted Therapy
    • 11.5.3.1. Erdafitinib
    • 11.5.3.2. Enfortumab Vedotin-ejfv
    • 11.5.3.3. Sacituzumab Govitecan
    • 11.5.3.4. Others
• 11.6. Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 11.6.1. Hospital Pharmacies
  • 11.6.2. Retail Pharmacies
  • 11.6.3. Specialty Pharmacies
  • 11.6.4. Online Pharmacies

12. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Industry Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 12.1. Key Highlights
• 12.2. Pricing Analysis
• 12.3. Middle East & Africa Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 12.3.1. GCC Countries
  • 12.3.2. South Africa
  • 12.3.3. Northern Africa
  • 12.3.4. Rest of MEA
• 12.4. Middle East & Africa Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 12.4.1. Low-grade Bladder Cancer
  • 12.4.2. High-grade Bladder Cancer
• 12.5. Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 12.5.1. Immunotherapy
    • 12.5.1.1. Bacillus Calmette-Guerin
    • 12.5.1.2. Avelumab
    • 12.5.1.3. Nivolumab
    • 12.5.1.4. Pembrolizumab
    • 12.5.1.5. Others
  • 12.5.2. Chemotherapy
    • 12.5.2.1. Mitomycin C
    • 12.5.2.2. Docetaxel
    • 12.5.2.3. Paclitaxel
    • 12.5.2.4. Cisplatin
    • 12.5.2.5. Others
  • 12.5.3. Targeted Therapy
    • 12.5.3.1. Erdafitinib
    • 12.5.3.2. Enfortumab Vedotin-ejfv
    • 12.5.3.3. Sacituzumab Govitecan
    • 12.5.3.4. Others
• 12.6. Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 12.6.1. Hospital Pharmacies
  • 12.6.2. Retail Pharmacies
  • 12.6.3. Specialty Pharmacies
  • 12.6.4. Online Pharmacies

13. Competition Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. Market Structure
  • 13.2.1. Competition Intensity Mapping
  • 13.2.2. Competition Dashboard
• 13.3. Company Profiles
  • 13.3.1. Pfizer Inc.
    • 13.3.1.1. Company Overview
    • 13.3.1.2. Product Portfolio/Offerings
    • 13.3.1.3. Key Financials
    • 13.3.1.4. SWOT Analysis
    • 13.3.1.5. Company Strategy and Key Developments
  • 13.3.2. Merck KGaA
  • 13.3.3. Merck & Co.
  • 13.3.4. AstraZeneca PLC
  • 13.3.5. Roche Holding AG (Genentech)
  • 13.3.6. Astellas Pharma Inc.
  • 13.3.7. J&J (Janssen Biotech)
  • 13.3.8. Cipla Inc.
  • 13.3.9. Amneal Pharma
  • 13.3.10. Bristol Myers Squibb Co.
  • 13.3.11. Dr. Reddy's Laboratories, Inc.
  • 13.3.12. Gilead Sciences Inc.
  • 13.3.13. Endo Pharma
  • 13.3.14. UroGen Pharma, Inc.
  • 13.3.15. Teva Pharmaceuticals (Actavis)

14. Appendix

• 14.1. Research Methodology
• 14.2. Research Assumptions
• 14.3. Acronyms and Abbreviations